Vaia Stavropoulou
Schlieren, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.
Journal: EJHaem
Published: June 06, 2024
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study.
Journal: Open forum infectious diseases
Published: November 10, 2023
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study.
Journal: British journal of clinical pharmacology
Published: December 16, 2022
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.
Journal: British journal of clinical pharmacology
Published: April 04, 2022
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy.
Journal: Cell metabolism
Published: December 10, 2019
Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.
Journal: Cancer discovery
Published: December 13, 2018
The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models.
Journal: HemaSphere
Published: May 17, 2018
A Novel Inducible Mouse Model of MLL-ENL-driven Mixed-lineage Acute Leukemia.
Journal: HemaSphere
Published: February 23, 2018
Aggressive leukemia driven by MLL-AF9.
Journal: Molecular & cellular oncology
Published: September 16, 2016
MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
Journal: Cancer cell
Published: March 30, 2015
Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis.
Journal: Cell stem cell
Published: July 18, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026